Tweet
Bone Marrow Transplant. 2015 Mar 23. doi: 10.1038/bmt.2015.47. [Epub ahead of print]
Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.
Ambati A1, Boas LS2, Ljungman P3, Testa L4, de Oliveira JF5, Aoun M6, Colturato V4, Maeurer M7, Machado CM8.
Author information
Abstract
Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or recipient pretransplant vaccination (n=40). Specific IgG was assessed by both hemagglutinin inhibition (HI) and, in 57 patients, by an indirect influenza-specific ELISA at specified times after HSCT. Vaccinated donors had seroprotective HI titers for Ags H1 and H3 (P<0.001) compared with the other groups at the time of donation. The titers against H1 (P=0.028) and H3 (P<0.001) were highest in the pretransplant recipient vaccination group until day 180 after transplantation. A significant difference was found in the specific Ig levels against pandemic H1N1 at 6 months after SCT (P=0.02). The mean IgG levels against pandemic H1N1 and generic H1N1 and H3N2 were highest in the pretransplant recipient vaccination group. We conclude that pretransplant recipient vaccination improved the influenza-specific seroprotection rates.Bone Marrow Transplantation advance online publication, 23 March 2015; doi:10.1038/bmt.2015.47.
PMID: 25798680 [PubMed - as supplied by publisher]
Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.
Ambati A1, Boas LS2, Ljungman P3, Testa L4, de Oliveira JF5, Aoun M6, Colturato V4, Maeurer M7, Machado CM8.
Author information
Abstract
Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or recipient pretransplant vaccination (n=40). Specific IgG was assessed by both hemagglutinin inhibition (HI) and, in 57 patients, by an indirect influenza-specific ELISA at specified times after HSCT. Vaccinated donors had seroprotective HI titers for Ags H1 and H3 (P<0.001) compared with the other groups at the time of donation. The titers against H1 (P=0.028) and H3 (P<0.001) were highest in the pretransplant recipient vaccination group until day 180 after transplantation. A significant difference was found in the specific Ig levels against pandemic H1N1 at 6 months after SCT (P=0.02). The mean IgG levels against pandemic H1N1 and generic H1N1 and H3N2 were highest in the pretransplant recipient vaccination group. We conclude that pretransplant recipient vaccination improved the influenza-specific seroprotection rates.Bone Marrow Transplantation advance online publication, 23 March 2015; doi:10.1038/bmt.2015.47.
PMID: 25798680 [PubMed - as supplied by publisher]